HUTCHMED (China) Limited (0013.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
HUTCHMED (China) Limited
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1811
First IPO Date
June 30, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Chig Fung Cheng | Acting Chief Executive Officer, Chief Financial Officer & Executive Director | 9.08M | 1967 |
| Weiguo Su | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) | 13.73M | 1959 |
| Charles George Rupert Nixon | Group General Counsel | 0 | 1970 |
| Yiling Cui | Executive Vice President & Head of Operations | 0 | N/A |
| David Ng | Head of Investor Relations & Capital Strategies | 0 | N/A |
| Xinhui Hu | Executive Vice President & Chief Technical Officer | 0 | 1973 |
| Qingmei Wang | Executive Vice President of Business Development & Strategic Alliances | 0 | 1963 |
| Thomas Fu | Senior Vice President of Global Quality | 0 | N/A |
| Kin Hung Lee | Senior Vice President of Corporate Management & Communications | 0 | 1977 |
| Selina Zhang | Senior Vice President of Global Human Resources | 0 | N/A |
Description
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Fruquintinib targets CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a broad spectrum of gastrointestinal and solid tumors. Another prominent compound, Surufatinib, is indicated for various neuroendocrine tumors (NETs) including pancreatic and non-pancreatic types, alongside biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and other solid tumors. Further pipeline assets feature HMPL-523, a spleen tyrosine kinase (Syk) inhibitor for treating hematological cancers and certain chronic immune diseases; HMPL-689, an inhibitor specifically targeting the PI3Kd isoform; and Tazemetostat, an EZH2 inhibitor utilized in the treatment of specific epithelioid sarcoma and follicular lymphoma patients. The company's development efforts also encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase (BTK) inhibitor; HMPL-453, aimed at intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; HMPL-653, developed for metastatic solid tumors and tenosynovial giant cell tumors; and the inhibitors Epitinib (HMPL-813) and Theliatinib (HMPL-309). HUTCHMED has forged strategic collaboration agreements with a number of significant pharmaceutical entities, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company, originally known as Hutchison China MediTech Limited, officially changed its name to HUTCHMED (China) Limited in May 2021.
